{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:51:02Z","timestamp":1787845862468,"version":"build-2784847793"},"reference-count":81,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["202836\/Z\/16\/Z"],"award-info":[{"award-number":["202836\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2015-0028"],"award-info":[{"award-number":["2015-0028"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001455","name":"American Foundation for Suicide Prevention","doi-asserted-by":"publisher","award":["DIG-1-037-19"],"award-info":[{"award-number":["DIG-1-037-19"]}],"id":[{"id":"10.13039\/100001455","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2016fobi50581"],"award-info":[{"award-number":["2016fobi50581"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\u03b2-blockers are widely used for treating cardiac conditions and are suggested for the treatment of anxiety and aggression, although research is conflicting and limited by methodological problems. In addition, \u03b2-blockers have been associated with precipitating other psychiatric disorders and suicidal behaviour, but findings are mixed. We aimed to examine associations between \u03b2-blockers and psychiatric and behavioural outcomes in a large population-based cohort in Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We conducted a population-based longitudinal cohort study using Swedish nationwide high-quality healthcare, mortality, and crime registers. We included 1,400,766 individuals aged 15 years or older who had collected \u03b2-blocker prescriptions and followed them for 8 years between 2006 and 2013. We linked register data on dispensed \u03b2-blocker prescriptions with main outcomes, hospitalisations for psychiatric disorders (not including self-injurious behaviour or suicide attempts), suicidal behaviour (including deaths from suicide), and charges of violent crime. We applied within-individual Cox proportional hazards regression to compare periods on treatment with periods off treatment within each individual in order to reduce possible confounding by indication, as this model inherently adjusts for all stable confounders (e.g., genetics and health history). We also adjusted for age as a time-varying covariate. In further analyses, we adjusted by stated indications, prevalent users, cardiac severity, psychiatric and crime history, individual \u03b2-blockers, \u03b2-blocker selectivity and solubility, and use of other medications. In the cohort, 86.8% (\n                      <jats:italic>n<\/jats:italic>\n                      = 1,215,247) were 50 years and over, and 52.2% (\n                      <jats:italic>n<\/jats:italic>\n                      = 731,322) were women. During the study period, 6.9% (\n                      <jats:italic>n<\/jats:italic>\n                      = 96,801) of the \u03b2-blocker users were hospitalised for a psychiatric disorder, 0.7% (\n                      <jats:italic>n<\/jats:italic>\n                      = 9,960) presented with suicidal behaviour, and 0.7% (\n                      <jats:italic>n<\/jats:italic>\n                      = 9,405) were charged with a violent crime. There was heterogeneity in the direction of results; within-individual analyses showed that periods of \u03b2-blocker treatment were associated with reduced hazards of psychiatric hospitalisations (hazard ratio [HR]: 0.92, 95% confidence interval [CI]: 0.91 to 0.93,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), charges of violent crime (HR: 0.87, 95% CI: 0.81 to 0.93,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and increased hazards of suicidal behaviour (HR: 1.08, 95% CI: 1.02 to 1.15,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.012). After stratifying by diagnosis, reduced associations with psychiatric hospitalisations during \u03b2-blocker treatment were mainly driven by lower hospitalisation rates due to depressive (HR: 0.92, 95% CI: 0.89 to 0.96,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and psychotic disorders (HR: 0.89, 95% CI: 0.85 to 0.93,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Reduced associations with violent charges remained in most sensitivity analyses, while associations with psychiatric hospitalisations and suicidal behaviour were inconsistent. Limitations include that the within-individual model does not account for confounders that could change during treatment, unless measured and adjusted for in the model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this population-wide study, we found no consistent links between \u03b2-blockers and psychiatric outcomes. However, \u03b2-blockers were associated with reductions in violence, which remained in sensitivity analyses. The use of \u03b2-blockers to manage aggression and violence could be investigated further.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004164","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T13:23:22Z","timestamp":1675171402000},"page":"e1004164","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Associations between \u03b2-blockers and psychiatric and behavioural outcomes: A population-based cohort study of 1.4 million individuals in Sweden"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5663-2010","authenticated-orcid":true,"given":"Yasmina","family":"Molero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7004-6942","authenticated-orcid":true,"given":"Sam","family":"Kaddoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-2067","authenticated-orcid":true,"given":"Ralf","family":"Kuja-Halkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-7434","authenticated-orcid":true,"given":"Brian M.","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-5365","authenticated-orcid":true,"given":"Seena","family":"Fazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"pmed.1004164.ref001","author":"K Farzam","year":"2021"},{"issue":"2","key":"pmed.1004164.ref002","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis","volume":"30","author":"SA Steenen","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"1","key":"pmed.1004164.ref003","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hfc.2010.08.006","article-title":"A review on the putative association between beta-blockers and depression","volume":"7","author":"DE Verbeek","year":"2011","journal-title":"Heart Fail Clin"},{"key":"pmed.1004164.ref004","unstructured":"Electronic Medicines Compendium. Summary of product characteristics for \u03b2-blockers [Internet]. Surrey: EMC; 2022 [Jan 04 2023]. Available from: https:\/\/www.medicines.org.uk\/emc\/."},{"issue":"1","key":"pmed.1004164.ref005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.31887\/DCNS.2007.9.1\/jchuffman","article-title":"Neuropsychiatric consequences of cardiovascular medications.","volume":"9","author":"JC Huffman","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"key":"pmed.1004164.ref006","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jad.2019.08.075","article-title":"Distinct effects of antihypertensives on depression in the real-world setting: a retrospective cohort study","volume":"259","author":"YY Cao","year":"2019","journal-title":"J Affect Disord"},{"issue":"2","key":"pmed.1004164.ref007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40264-021-01140-5","article-title":"\u03b2-blockers and the risk of depression: a matched case\u2013control study","volume":"45","author":"D Bornand","year":"2022","journal-title":"Drug Safety"},{"issue":"5","key":"pmed.1004164.ref008","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/HYPERTENSIONAHA.116.08188","article-title":"Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders","volume":"68","author":"AH Boal","year":"2016","journal-title":"Hypertension"},{"key":"pmed.1004164.ref009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/DDDT.S124497","article-title":"Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders","volume":"11","author":"X Liu","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"50","key":"pmed.1004164.ref010","doi-asserted-by":"crossref","first-page":"e18331","DOI":"10.1097\/MD.0000000000018331","article-title":"Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients","volume":"98","author":"L Wu","year":"2019","journal-title":"Medicine"},{"issue":"3","key":"pmed.1004164.ref011","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.0306-5251.2001.01442.x","article-title":"Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors","volume":"52","author":"HT S\u00f8rensen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pmed.1004164.ref012","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/JCP.0000000000000695","article-title":"Lipophilic \u03b2-Blockers and suicide in the elderly","volume":"37","author":"JS Zipursky","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"pmed.1004164.ref013","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1089\/cap.2016.0079","article-title":"Beta-blockers for exams identify students at high risk of psychiatric morbidity","volume":"27","author":"JH Butt","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"pmed.1004164.ref014","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0269881118756245","article-title":"Propranolol for treating emotional, behavioural, autonomic dysregulation in children and adolescents with autism spectrum disorders.","volume":"32","author":"I Sagar-Ouriaghli","year":"2018","journal-title":"J Psychopharmacol"},{"key":"pmed.1004164.ref015","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ijcard.2015.11.032","article-title":"Antidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression","volume":"203","author":"C Brouwers","year":"2016","journal-title":"Int J Cardiol"},{"issue":"13","key":"pmed.1004164.ref016","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1089\/neu.2018.6244","article-title":"Prophylaxis pharmacotherapy to prevent the onset of post-traumatic brain injury depression: a systematic review","volume":"36","author":"FJ Clay","year":"2019","journal-title":"J Neurotrauma"},{"issue":"4","key":"pmed.1004164.ref017","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.120.15605","article-title":"Antihypertensive drugs and risk of depression: a nationwide population-based study","volume":"76","author":"LV Kessing","year":"2020","journal-title":"Hypertension"},{"issue":"5","key":"pmed.1004164.ref018","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.amjcard.2019.05.054","article-title":"Frequency of utilization of beta blockers in patients with heart failure and depression and their effect on mortality","volume":"124","author":"C Kim","year":"2019","journal-title":"Am J Cardiol"},{"issue":"3","key":"pmed.1004164.ref019","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jad.2011.09.047","article-title":"Beta blocker therapy is associated with reduced depressive symptoms 12 months post percutaneous coronary intervention","volume":"136","author":"LC Battes","year":"2012","journal-title":"J Affect Disord"},{"key":"pmed.1004164.ref020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ahj.2019.11.003","article-title":"The effect of metoprolol and aspirin on cardiovascular risk in bereavement: a randomized controlled trial","volume":"220","author":"GH Tofler","year":"2020","journal-title":"Am Heart J"},{"key":"pmed.1004164.ref021","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2015.11.018","article-title":"Initiation of \u03b2-blocker therapy and depression after acute myocardial infarction","volume":"174","author":"AM Ranchord","year":"2016","journal-title":"Am Heart J"},{"issue":"11","key":"pmed.1004164.ref022","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.jacc.2006.07.056","article-title":"Beta-blockers and depression after myocardial infarction: a multicenter prospective study","volume":"48","author":"JP van Melle","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"pmed.1004164.ref023","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1745-7599.2006.00164.x","article-title":"Beta-blocker medication usage in older women after myocardial infarction.","volume":"18","author":"PB Crane","year":"2006","journal-title":"J Am Acad Nurse Pract"},{"issue":"6","key":"pmed.1004164.ref024","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00228-007-0293-5","article-title":"Cardiovascular drugs and the risk of suicide: a nested case-control study","volume":"63","author":"T Callr\u00e9us","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"pmed.1004164.ref025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JCP.0b013e31820482c4","article-title":"\u03b2-blockers and the risk of incident depression in the elderly","volume":"31","author":"HJ Luijendijk","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"pmed.1004164.ref026","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(00)00304-1","article-title":"The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension","volume":"108","author":"EJ P\u00e9rez-Stable","year":"2000","journal-title":"Am J Med"},{"issue":"3","key":"pmed.1004164.ref027","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.288.3.351","article-title":"Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction","volume":"288","author":"DT Ko","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"pmed.1004164.ref028","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1161\/HYPERTENSIONAHA.120.16590","article-title":"Do \u03b2-blockers cause depression? Systematic review and meta-analysis of psychiatric adverse events during \u03b2-blocker therapy","volume":"77","author":"TG Riemer","year":"2021","journal-title":"Hypertension"},{"issue":"10","key":"pmed.1004164.ref029","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/appi.ajp.158.10.1725","article-title":"Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study","volume":"158","author":"MB Stein","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"6","key":"pmed.1004164.ref030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/jts.20270","article-title":"Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients","volume":"20","author":"MB Stein","year":"2007","journal-title":"J Trauma Stress"},{"issue":"2","key":"pmed.1004164.ref031","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1592\/phco.26.2.162","article-title":"Do randomized controlled trials always trump case reports? A second look at propranolol and depression","volume":"26","author":"JJ Steffensmeier","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"2","key":"pmed.1004164.ref032","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.CRD.0000053453.89776.2D","article-title":"Neuropsychiatric effects of cardiovascular drug therapy.","volume":"11","author":"S Keller","year":"2003","journal-title":"Cardiol Rev"},{"issue":"2","key":"pmed.1004164.ref033","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1037\/a0018059","article-title":"Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options","volume":"18","author":"RM Nevels","year":"2010","journal-title":"Exp Clin Psychopharmacol"},{"issue":"5","key":"pmed.1004164.ref034","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1017\/S1092852914000054","article-title":"The psychopharmacology of violence: making sensible decisions","volume":"19","author":"L Citrome","year":"2014","journal-title":"CNS Spectr"},{"issue":"2","key":"pmed.1004164.ref035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004850-200103000-00006","article-title":"Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study","volume":"16","author":"N Caspi","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"pmed.1004164.ref036","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.spen.2004.07.006","article-title":"Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder","volume":"11","author":"MG Aman","year":"2004","journal-title":"Semin Pediatr Neurol"},{"issue":"1","key":"pmed.1004164.ref037","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S1461145703003973","article-title":"Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.","volume":"7","author":"J Biederman","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"pmed.1004164.ref038","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002512-200825050-00003","article-title":"Alternatives to atypical antipsychotics for the management of dementia-related agitation","volume":"25","author":"MJ Passmore","year":"2008","journal-title":"Drugs Aging"},{"issue":"2","key":"pmed.1004164.ref039","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/JCP.0000000000001175","article-title":"The safety and effectiveness of high-dose propranolol as a treatment for challenging behaviors in individuals with autism spectrum disorders","volume":"40","author":"EB London","year":"2020","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"pmed.1004164.ref040","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1016\/j.ridd.2013.08.015","article-title":"Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: a systematic review","volume":"34","author":"F Ward","year":"2013","journal-title":"Res Dev Disabil"},{"issue":"3","key":"pmed.1004164.ref041","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02699052.2017.1419377","article-title":"Pharmacological management of agitation among individuals with moderate to severe acquired brain injury: A systematic review","volume":"32","author":"S Mehta","year":"2018","journal-title":"Brain Inj"},{"issue":"1","key":"pmed.1004164.ref042","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.rehab.2015.11.001","article-title":"Care management of the agitation or aggressiveness crisis in patients with TBI. Systematic review of the literature and practice recommendations","volume":"59","author":"J Luaut\u00e9","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"issue":"1","key":"pmed.1004164.ref043","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rehab.2015.10.003","article-title":"Drugs for behavior disorders after traumatic brain injury: systematic review and expert consensus leading to French recommendations for good practice","volume":"59","author":"D Plantier","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"issue":"7","key":"pmed.1004164.ref044","doi-asserted-by":"crossref","first-page":"e0159366","DOI":"10.1371\/journal.pone.0159366","article-title":"Use of pharmacy sales data to assess changes in prescription- and payment-related factors that promote adherence to medications commonly used to treat hypertension, 2009 and 2014.","volume":"11","author":"M Ritchey","year":"2016","journal-title":"PLoS ONE"},{"issue":"2","key":"pmed.1004164.ref045","doi-asserted-by":"crossref","DOI":"10.3390\/pharmacy6020043","article-title":"Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice","volume":"6","author":"AV Fuentes","year":"2018","journal-title":"Pharmacy"},{"issue":"8","key":"pmed.1004164.ref046","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2006.06.055","article-title":"Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes","volume":"48","author":"T Rutledge","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"pmed.1004164.ref047","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/HRP.0000000000000162","article-title":"Depression and anxiety in heart failure: a review","volume":"26","author":"CM Celano","year":"2018","journal-title":"Harv Rev Psychiatry"},{"issue":"11","key":"pmed.1004164.ref048","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cardfail.2018.07.006","article-title":"Is heart failure associated with risk of suicide?","volume":"24","author":"CH Liu","year":"2018","journal-title":"J Card Fail."},{"issue":"12","key":"pmed.1004164.ref049","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1517\/14740338.2015.1102225","article-title":"The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?","volume":"14","author":"RG Kiel","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"pmed.1004164.ref050","doi-asserted-by":"crossref","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"I Petersen","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"pmed.1004164.ref051","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research","volume":"31","author":"JF Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"pmed.1004164.ref052","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"HL Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"pmed.1004164.ref053","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register.","volume":"11","author":"JF Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"7","key":"pmed.1004164.ref054","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish prescribed drug register\u2014opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"B Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"pmed.1004164.ref055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"JF Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"pmed.1004164.ref056","unstructured":"Brottsf\u00f6rebyggande r\u00e5det. Kriminalstatistik 2018. Personer lagf\u00f6rda f\u00f6r brott. Slutlig statistik. Stockholm: Brottsf\u00f6rebyggande r\u00e5det URN: NBN: SE: BRA-835; 2019. p. 1\u201364."},{"issue":"4","key":"pmed.1004164.ref057","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","article-title":"The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research","volume":"34","author":"JF Ludvigsson","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"pmed.1004164.ref058","doi-asserted-by":"crossref","DOI":"10.4135\/9781412993869","volume-title":"Fixed effects regression models","author":"PD Allison","year":"2009"},{"key":"pmed.1004164.ref059","unstructured":"Socialstyrelsen. L\u00e4kemedelsregistret [Internet]. Stockholm: Socialstyrelsen; 2020 [Jan 04 2023]. Available from: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/lakemedelsregistret\/."},{"issue":"9","key":"pmed.1004164.ref060","doi-asserted-by":"crossref","first-page":"e1001875","DOI":"10.1371\/journal.pmed.1001875","article-title":"Selective serotonin reuptake inhibitors and violent crime: a cohort study","volume":"12","author":"Y Molero","year":"2015","journal-title":"PLoS Med"},{"key":"pmed.1004164.ref061","doi-asserted-by":"crossref","first-page":"l2147","DOI":"10.1136\/bmj.l2147","article-title":"Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden","volume":"365","author":"Y Molero","year":"2019","journal-title":"BMJ"},{"key":"pmed.1004164.ref062","unstructured":"Sveriges Riksdag. F\u00f6rordning (2002:687) om l\u00e4kemedelsf\u00f6rm\u00e5ner m.m. [Internet]. Stockholm: Sveriges Riksdag; 2002 [Jan 04 2023]. Available from: https:\/\/www.riksdagen.se\/sv\/dokument-lagar\/dokument\/svensk-forfattningssamling\/forordning-2002687-om-lakemedelsformaner-mm_sfs-2002-687."},{"issue":"21","key":"pmed.1004164.ref063","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","article-title":"Medication for attention deficit-hyperactivity disorder and criminality","volume":"367","author":"P Lichtenstein","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1004164.ref064","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ije\/dyt221","article-title":"Fixed effects analysis of repeated measures data","volume":"43","author":"FI Gunasekara","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"1","key":"pmed.1004164.ref065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.31887\/DCNS.2018.20.1\/dnaber","article-title":"Psychiatric sequelae of cardiac arrest","volume":"20","author":"D Naber","year":"2018","journal-title":"Dialogues Clin Neurosci"},{"issue":"5","key":"pmed.1004164.ref066","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/joim.13025","article-title":"The association between heart diseases and suicide: a nationwide cohort study","volume":"287","author":"BD Petersen","year":"2020","journal-title":"J Intern Med"},{"issue":"6","key":"pmed.1004164.ref067","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1016\/j.ijcard.2013.08.012","article-title":"Associations between DSM-IV mental disorders and subsequent heart disease onset: beyond depression","volume":"168","author":"KM Scott","year":"2013","journal-title":"Int J Cardiol"},{"issue":"4","key":"pmed.1004164.ref068","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/0269881108097714","article-title":"Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review","volume":"24","author":"R Whale","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"1\u20133","key":"pmed.1004164.ref069","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-0327(02)00404-4","article-title":"Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials","volume":"79","author":"J Ballesteros","year":"2004","journal-title":"J Affect Disord"},{"issue":"4","key":"pmed.1004164.ref070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"G Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"1","key":"pmed.1004164.ref071","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.wad.0000155067.16313.5e","article-title":"Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study","volume":"19","author":"ER Peskind","year":"2005","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"pmed.1004164.ref072","article-title":"Pharmacological management for agitation and aggression in people with acquired brain injury","author":"S Fleminger","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"pmed.1004164.ref073","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14789949.2017.1284886","article-title":"Violence prevention in psychiatry: an umbrella review of interventions in general and forensic psychiatry","volume":"28","author":"A Wolf","year":"2017","journal-title":"J Forens Psychiatry Psychol"},{"issue":"1","key":"pmed.1004164.ref074","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1586\/ern.10.180","article-title":"The pharmacological management of violence in schizophrenia: a structured review","volume":"11","author":"A Topiwala","year":"2011","journal-title":"Expert Rev Neurother"},{"issue":"7","key":"pmed.1004164.ref075","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00268-017-3935-5","article-title":"Does Beta-blockade reduce the risk of depression in patients with isolated severe extracranial injuries?","volume":"41","author":"R Ahl","year":"2017","journal-title":"World J Surg"},{"issue":"1","key":"pmed.1004164.ref076","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0006-3223(01)01294-X","article-title":"Pharmacotherapy of social anxiety disorder","volume":"51","author":"C Blanco","year":"2002","journal-title":"Biol Psychiatry"},{"issue":"21","key":"pmed.1004164.ref077","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/eurheartj\/eht462","article-title":"Depression and cardiovascular disease: a clinical review","volume":"35","author":"DL Hare","year":"2013","journal-title":"Eur Heart J"},{"issue":"23","key":"pmed.1004164.ref078","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1161\/CIRCULATIONAHA.110.956136","article-title":"Myocardial infarction and risk of suicide: a population-based case-control study","volume":"122","author":"KK Larsen","year":"2010","journal-title":"Circulation"},{"key":"pmed.1004164.ref079","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jocn.2019.07.062","article-title":"Suicide risk in chronic heart failure patients and its association with depression, hopelessness and self esteem","volume":"68","author":"H Korkmaz","year":"2019","journal-title":"J Clin Neurosci"},{"key":"pmed.1004164.ref080","unstructured":"Eurostat. Cardiovascular diseases statistics [Internet]. Luxembourg: Eurostat Statistics Explained; 2022 [Jan 04 2023]. Available from: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Cardiovascular_diseases_statistics#Self-reporting_of_hypertensive_diseases."},{"issue":"1","key":"pmed.1004164.ref081","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/pds.1216","article-title":"Prescribing for chronic heart failure in Europe: does the country make the difference? A European survey","volume":"16","author":"HB Sturm","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T13:24:22Z","timestamp":1675171462000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004164","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]}}}